Genomic statistics have shifted from “interesting” to genuinely actionable, from TP53 mutations appearing in 50% of human cancers to noninvasive prenatal testing flagging trisomy 21 with 99.2% sensitivity at 10 weeks. Meanwhile, the underlying variation is vast and measurable, with 84.7 million SNPs and millions of indels tracked across just a few thousand people. This post connects those clinical signals to population-scale databases and modern sequencing limits, where even the smallest variants can change risk, treatment response, and what we see under the microscope.
Key Takeaways
- TP53 mutations occur in 50% of all human cancers, highest prognostic impact
- KRAS mutations drive 90% of pancreatic ductal adenocarcinomas
- EGFR exon 19 deletions confer 80% response to TKIs in NSCLC
- The 1000 Genomes Project identified 84.7 million SNPs and 3.6 million short indels across 2,504 individuals
- gnomAD database v3 catalogs 713,836 exomes and 76,156 genomes with 407 million variants
- Common SNPs (MAF>1%) number 93 million in non-Finnish Europeans per gnomAD
- Pharmacogenomics variants in CYP2D6 affect 7-10% of Caucasians as poor metabolizers
- BRCA1/2 pathogenic variants confer 72% lifetime breast cancer risk in females
- Polygenic risk scores predict 10-20% variance in coronary artery disease risk
- The human genome consists of approximately 3.2 billion base pairs of DNA sequence, distributed across 23 pairs of chromosomes
- Over 99.9% of the DNA sequence is identical among all humans, with the remaining 0.1% accounting for individual differences
- The average human gene density is about 1 gene per 100,000 base pairs, totaling around 20,000-25,000 protein-coding genes
- Illumina sequencing platforms achieve read lengths up to 300 base pairs with error rates below 0.1% at Q30 quality
- Oxford Nanopore Technologies provide long reads averaging 10-100 kb with 99% raw accuracy after basecalling
- PacBio HiFi reads deliver 15-20 kb lengths at >99.9% accuracy using circular consensus sequencing
Genomic insights tie key mutations and improved sequencing to clearer cancer risk, diagnosis, and treatment.
Related reading
01 · Category
Cancer Genomics20 stats
01
TP53 mutations occur in 50% of all human cancers, highest prognostic impact
02
KRAS mutations drive 90% of pancreatic ductal adenocarcinomas
03
EGFR exon 19 deletions confer 80% response to TKIs in NSCLC
04
BRCA1/2 mutations sensitize 15% high-grade serous ovarian cancers to platinum
05
Tumor neoantigen burden correlates with immunotherapy response r=0.4 in melanoma
06
MSI status high in 15% colorectal cancers predicts 50% immunotherapy benefit
07
Fusion genes like EML4-ALK occur in 5% NSCLC, responsive to crizotinib 74%
08
IDH1 R132H mutation in 70-80% lower-grade gliomas alters epigenome
09
MYC amplification in 15% triple-negative breast cancers drives proliferation
10
PTEN loss in 40% prostate cancers activates PI3K pathway
11
BRAF V600E mutation in 50% melanomas responds 60% to vemurafenib
12
Chromothripsis shatters 1-2 chromosomes in 25% cancers creating thousands of rearrangements
13
APOBEC mutagenesis signatures in 30% cancers generate kataegis clusters
14
HRD score >42 predicts PARP inhibitor response in 50% ovarian cancers
15
TERT promoter mutations in 70% melanomas and 80% glioblastomas activate telomerase
16
PIK3CA mutations in 40% breast cancers, mostly HR+ subtype
17
5-methylcytosine alterations hypomethylate 20% enhancers in cancer epigenomes
18
Aneuploidy affects 60% tumors with 10-50 chromosome arm alterations average
19
CTNNB1 mutations stabilize beta-catenin in 90% Wnt-driven liver cancers
20
Homologous recombination deficiency prevalent in 20% triple-negative breast cancers
Interpretation
Cancer Genomics Interpretation
Across cancer genomics, a small set of key mutations and biomarkers accounts for outsized clinical impact, from TP53 showing up in 50% of cancers to KRAS driving 90% of pancreatic ductal adenocarcinomas and MSI high predicting 50% immunotherapy benefit in 15% of colorectal cases.
02 · Category
Genetic Variation20 stats
01
The 1000 Genomes Project identified 84.7 million SNPs and 3.6 million short indels across 2,504 individuals
02
gnomAD database v3 catalogs 713,836 exomes and 76,156 genomes with 407 million variants
03
Common SNPs (MAF>1%) number 93 million in non-Finnish Europeans per gnomAD
04
Structural variants affect 20 kb per genome on average, totaling 2.5% of genomic differences
05
Copy number variants >50 bp cover 12% of the human genome variation
06
Inversions occur at 12 kb per haploid genome, impacting gene regulation
07
Mobile element insertions contribute 1 in 1000 germline mutations
08
Somatic mutation burden in normal cells averages 100-1000 per exome by age 70
09
Loss-of-function variants intolerant genes number 3,230 with pLI >=0.9 in gnomAD
10
Haplotype blocks in Europeans span 10-100 kb with LD r2>0.8
11
African populations show 15% higher heterozygosity at 1.2 x 10^-3 per site
12
De novo mutations rate is 1.29 x 10^-8 per bp per generation from trio sequencing
13
Mosaic variants detected in 1-2% of bulk cells arise at 10^-7 per cell division
14
Rare variants (MAF<0.1%) explain 20-30% of heritability for complex traits
15
Tandem repeat expansions cause 40+ diseases with repeat lengths >50 units
16
Population bottleneck 50-100kya reduced diversity by 20% outside Africa
17
Neanderthal admixture contributes 1-2% genome in Eurasians with 96 large blocks
18
Polygenic risk scores correlate 0.1-0.4 with disease incidence across ancestries
19
CRISPR off-target editing rate <0.1% with high-fidelity Cas9 variants
20
Genome-wide association studies have identified 12,000+ loci for 1,000+ traits
Interpretation
Genetic Variation Interpretation
Across major genetic variation datasets, the sheer scale of variation is clear with 407 million variants in gnomAD v3 and 93 million common SNPs in non-Finnish Europeans, showing that genetic variation is dominated by widespread small changes alongside smaller but meaningful structural differences like 2.5% of genome divergence from structural variants and 12% coverage from copy number variants.
03 · Category
Genomic Medicine22 stats
01
Pharmacogenomics variants in CYP2D6 affect 7-10% of Caucasians as poor metabolizers
02
BRCA1/2 pathogenic variants confer 72% lifetime breast cancer risk in females
03
Polygenic risk scores predict 10-20% variance in coronary artery disease risk
04
Non-invasive prenatal testing detects trisomy 21 with 99.2% sensitivity at 10 weeks
05
Tumor mutational burden averages 4 mut/Mb in non-smokers vs 9 in smokers for lung cancer
06
CAR-T therapy targets CD19 with 83% remission in refractory B-ALL patients
07
Germline TP53 mutations cause Li-Fraumeni syndrome with 90% cancer penetrance
08
CRISPR-Cas9 editing corrects 20-80% of DMD mutations in patient cardiomyocytes
09
Liquid biopsy ctDNA detects 87% of stage II colorectal cancers pre-recurrence
10
HLA-matched allogeneic transplants achieve 60% 5-year survival in AML
11
APOE ε4 allele increases Alzheimer's risk 3-15 fold depending on copies
12
PARP inhibitors extend progression-free survival 7 months in BRCA-mutated ovarian cancer
13
Whole exome sequencing diagnoses 31% of rare disease trios undiagnosed clinically
14
Base editing corrects 44% of sickle cell mutations in hematopoietic stem cells
15
MSI-high tumors respond to pembrolizumab with 40% objective response rate
16
PCSK9 inhibitors reduce LDL-C by 60% in familial hypercholesterolemia
17
Newborn genomic screening identifies 13% actionable findings in 1600 infants
18
RNA-seq on tumors reveals 25% novel fusions missed by DNA methods
19
AAV gene therapy restores 40% RPE65 function in Leber congenital amaurosis
20
Imatinib achieves 98% major cytogenetic response in CML Philadelphia-positive
21
70-80% of lung adenocarcinomas harbor targetable EGFR, ALK, or ROS1 alterations
22
Whole genome sequencing reduces time to diagnosis by 3 months in critically ill children
Interpretation
Genomic Medicine Interpretation
Genomic Medicine is rapidly moving from risk prediction to actionable care, as illustrated by CYP2D6 poor metabolizers affecting 7 to 10% of Caucasians and BRCA1 or BRCA2 variants raising lifetime breast cancer risk to 72% while tools like non invasive prenatal testing reach 99.2% sensitivity for trisomy 21.
More related reading
04 · Category
Human Genome29 stats
01
The human genome consists of approximately 3.2 billion base pairs of DNA sequence, distributed across 23 pairs of chromosomes
02
Over 99.9% of the DNA sequence is identical among all humans, with the remaining 0.1% accounting for individual differences
03
The average human gene density is about 1 gene per 100,000 base pairs, totaling around 20,000-25,000 protein-coding genes
04
Non-coding RNA genes make up about 9% of the human genome, including over 18,000 long non-coding RNAs
05
The Y chromosome in males contains only about 59 million base pairs, compared to the X chromosome's 155 million
06
Mitochondrial DNA in humans is a circular 16,569 base pair genome inherited maternally
07
The human genome has about 1.5% of its sequence coding for proteins, with the rest being regulatory or non-coding
08
Introns constitute roughly 25-30% of the human genome, varying greatly between genes
09
The largest human chromosome, chromosome 1, spans 249 million base pairs and contains about 2,000 genes
10
Telomeres at chromosome ends consist of repetitive TTAGGG sequences, shortening by 50-200 base pairs per cell division
11
Centromeres, essential for chromosome segregation, contain alpha-satellite DNA repeats totaling 3-5% of the genome
12
The haploid human genome size is 3.1-3.3 gigabases, measured precisely by the Genome Reference Consortium
13
About 8% of the human genome derives from ancient retroviral insertions known as endogenous retroviruses
14
Pseudogenes number over 14,000 in the human genome, remnants of functional genes
15
The genome-wide CpG dinucleotide frequency is suppressed to 20-25% of expectation due to methylation
16
Chromosome 19 has the highest gene density at 1 gene per 40,000 base pairs among autosomes
17
The human genome contains around 1.2 million known SNPs in coding regions
18
Histone modifications regulate about 80% of the genome through chromatin accessibility
19
The number of microRNA genes in humans is estimated at 1,881 loci producing 2,654 precursors
20
Tandem repeats account for 8% of the human genome, including microsatellites and minisatellites
21
The X chromosome inactivation center spans 1 Mb and includes the XIST gene crucial for silencing
22
Human genome assembly GRCh38 includes 3.1 Gb of sequence with over 99% coverage of euchromatin
23
Approximately 4.8% of the genome is annotated as conserved elements across mammals
24
The genome has over 200,000 regulatory elements identified by ENCODE
25
Alu elements, SINEs, comprise 10.7% of the human genome, totaling over 1 million copies
26
LINE-1 retrotransposons make up 17.2% of the genome, with about 500,000 copies
27
The major histocompatibility complex on chromosome 6 spans 3.6 Mb with over 200 genes
28
HOX gene clusters on chromosomes 2,7,12,17 total 39 genes regulating body plan
29
The genome-wide mutation rate is about 1.2 × 10^-8 per base pair per generation
Interpretation
Human Genome Interpretation
Within the human genome, a 3.2 billion base pair blueprint is highly shared across people with over 99.9% DNA sequence identical, while just 0.1% variation drives the individual differences that make each person unique.
05 · Category
Sequencing Technologies20 stats
01
Illumina sequencing platforms achieve read lengths up to 300 base pairs with error rates below 0.1% at Q30 quality
02
Oxford Nanopore Technologies provide long reads averaging 10-100 kb with 99% raw accuracy after basecalling
03
PacBio HiFi reads deliver 15-20 kb lengths at >99.9% accuracy using circular consensus sequencing
04
The cost of whole genome sequencing dropped to $600per genome in 2023 using NovaSeq systems
05
BGI's DNBSEQ platforms sequence at 35 Tb per run with 150 bp paired-end reads
06
Ion Torrent semiconductor sequencing detects pH changes for 400 bp reads at speeds of 4 hours per run
07
Single-molecule real-time sequencing by PacBio records polymerase kinetics for 20 kb reads
08
10x Genomics Chromium enables linked-reads for phasing haplotypes up to 1 Mb with barcode efficiency >98%
09
Element Biosciences AVITI system achieves 1.6 Tb output per flow cell with 99.3% raw accuracy
10
MGI Tech's DNBSEQ-T7 yields 12 Tb per run for ultra-high throughput WGS
11
CRISPR-based sequencing enrichment boosts target coverage 1000-fold for rare variant detection
12
Third-generation sequencers like MinION achieve 99.5% specificity for methylation detection without bisulfite
13
NovaSeq X series reduces WGS cost to $200per genome at 30x coverage
14
Long-read assemblies resolve 99% of human centromeres previously unmappable
15
Optical mapping by Bionano provides 150 kb molecule lengths for structural variant detection >95% accuracy
16
Ultima Genomics UG100 sequencers target $100genome via high-density patterning
17
Nanopore PromethION generates 290 Gb per flow cell with 400b/s throughput per channel
18
Hypercooling in NovaSeq improves cluster density to 400 million per tile
19
Phasing accuracy reaches 99.9% with trio-binning on long-read data
20
Single-cell ATAC-seq captures 50,000 cells per run profiling chromatin accessibility
Interpretation
Sequencing Technologies Interpretation
Across today’s sequencing technologies, performance is being pushed by a clear tradeoff between read length and accuracy and speed, with Illumina reaching 300 bp at Q30 below 0.1% error while long read platforms like Nanopore average 10 to 100 kb at 99% accuracy, PacBio HiFi hits 15 to 20 kb at over 99.9% accuracy, and whole genome costs fell to $600 in 2023 using NovaSeq systems.
report visual · Breakdown
Key genomic markers across cancers
High-frequency tumor mutations and biomarkers link to prognosis and treatment response across major cancer types.
50%
TP53 mutations occur in 50% of all human cancers, highest prognostic impact
50%
BRAF V600E mutation in 50% melanomas responds 60% to vemurafenib
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Catherine Wu. (2026, February 13). Genomic Statistics. Gitnux. https://gitnux.org/genomic-statistics
MLA
Catherine Wu. "Genomic Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/genomic-statistics.
Chicago
Catherine Wu. 2026. "Genomic Statistics." Gitnux. https://gitnux.org/genomic-statistics.
Sources & references
28 datasets cited across this report · attribution is report-level